These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9889213)

  • 21. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy.
    Segondy M; Izopet J; Pellegrin I; Montes B; Dumon B; Pasquier C; Peeters M; Fleury HJ; Puel J; Reynes J
    J Clin Microbiol; 1998 Nov; 36(11):3392-5. PubMed ID: 9774604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma.
    Sun R; Ku J; Jayakar H; Kuo JC; Brambilla D; Herman S; Rosenstraus M; Spadoro J
    J Clin Microbiol; 1998 Oct; 36(10):2964-9. PubMed ID: 9738051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA.
    Pasternak AO; Adema KW; Bakker M; Jurriaans S; Berkhout B; Cornelissen M; Lukashov VV
    J Clin Microbiol; 2008 Jul; 46(7):2206-11. PubMed ID: 18463204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
    Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
    AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
    [No Abstract]   [Full Text] [Related]  

  • 26. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
    Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F
    J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of three commercial assays for the quantification of HIV-1 RNA in plasma from individuals infected with different HIV-1 subtypes.
    Chew CB; Herring BL; Zheng F; Browne C; Saksena NK; Cunningham AL; Dwyer DE
    J Clin Virol; 1999 Oct; 14(2):87-94. PubMed ID: 10588451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa.
    Stevens G; Rekhviashvili N; Scott LE; Gonin R; Stevens W
    J Clin Microbiol; 2005 Feb; 43(2):857-61. PubMed ID: 15695692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid quantitative detection of Human immunodeficiency virus type 1 by a reverse transcription-loop-mediated isothermal amplification assay.
    Zeng Y; Zhang X; Nie K; Ding X; Ring BZ; Xu L; Dai L; Li X; Ren W; Shi L; Ma X
    Gene; 2014 May; 541(2):123-8. PubMed ID: 24630968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A simple competitive RT-PCR assay for quantitation of HIV-1 subtype B and non-B RNA in plasma.
    Hamatake M; Nishizawa M; Yamamoto N; Kato S; Sugiura W
    J Virol Methods; 2007 Jun; 142(1-2):113-7. PubMed ID: 17367872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simple monitoring of antiretroviral therapy with a signal-amplification-boosted HIV-1 p24 antigen assay with heat-denatured plasma.
    Böni J; Opravil M; Tomasik Z; Rothen M; Bisset L; Grob PJ; Lüthy R; Schüpbach J
    AIDS; 1997 May; 11(6):F47-52. PubMed ID: 9143600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy.
    Andreoni M; Sarmati L; Ercoli L; Nicastri E; Giannini G; Galluzzo C; Pirillo MF; Vella S
    AIDS Res Hum Retroviruses; 1997 May; 13(7):555-61. PubMed ID: 9135873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of HIV-1 proviral DNA in patients with undetectable plasma viremia over long-term highly active antiretroviral therapy.
    Debiaggi M; Zara F; Pistorio A; Bruno R; Sacchi P; Patruno SF; Achilli G; Romero E; Filice G
    Int J Infect Dis; 2000; 4(4):187-93. PubMed ID: 11231180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy.
    Andreoni M; Parisi SG; Sarmati L; Nicastri E; Ercoli L; Mancino G; Sotgiu G; Mannazzu M; Trevenzoli M; Tridente G; Concia E; Aceti A
    AIDS; 2000 Jan; 14(1):23-9. PubMed ID: 10714564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma viral RNA assay in HIV-1 group O infection by real-time PCR.
    Gueudin M; Plantier JC; Damond F; Roques P; Mauclère P; Simon F
    J Virol Methods; 2003 Oct; 113(1):43-9. PubMed ID: 14500126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma.
    Revets H; Marissens D; de Wit S; Lacor P; Clumeck N; Lauwers S; Zissis G
    J Clin Microbiol; 1996 May; 34(5):1058-64. PubMed ID: 8727875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluorogenic LUX primer for quantitation of HIV-1 by real-time RT-PCR.
    Rekhviashvili N; Stevens G; Scott L; Stevens W
    Mol Biotechnol; 2006 Feb; 32(2):101-10. PubMed ID: 16444011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma.
    Murphy DG; Côté L; Fauvel M; René P; Vincelette J
    J Clin Microbiol; 2000 Nov; 38(11):4034-41. PubMed ID: 11060065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.